2026-10-06
GSK is a British pharmaceutical and vaccine maker with £32.7bn of 2025 sales. It earns money in three areas: Specialty Medicines (£13.5bn, led by HIV through its majority-owned ViiV Healthcare, plus respiratory, immunology and oncology), Vaccines (£9.2bn, led by the shingles vaccine Shingrix and the RSV vaccine Arexvy) and General Medicines (£10.0bn, mostly mature inhalers such as Trelegy). It spun off its consumer arm, Haleon, in 2022. The investment debate centres on one question: can new drugs replace sales of dolutegravir, its HIV backbone, when patents lapse between 2028 and 2030? Management promises more than £40bn of sales by 2031.
- Intrinsic value, DCF: US$53 per ADS (range US$41 to US$64)
- Intrinsic value, MEV: US$52 per ADS (range US$43 to US$61)
- PE: 14.6x trailing reported earnings; about 9.1x 2026 core earnings guidance. The market doubts both the quality of “core” earnings and their durability past 2028.
- PEG: not meaningful. Core EPS growth of 7% to 9% this year, falling towards zero during the patent cliff, gives a PEG of roughly 1.0 to 1.3 depending on the period chosen.
- PEGY: about 0.8 on 2026 numbers (9.1x PE divided by 8% growth plus a 4.1% yield), indicating fair-to-cheap value once the dividend is counted.
- Valuation confidence: Medium
At-a-Glance Scorecard
| Item | Assessment |
|---|---|
| Business model simple and sustainable? | Yes, but each drug has a finite patent life |
| Moat present? | Yes: patents, regulatory barriers, vaccine manufacturing scale |
| Management competent and aligned? | Yes, cautiously; new CEO since January 2026, insider ownership 0.06% |
| Intrinsic value, DCF (range) | US$41 to US$64, point US$53 |
| Intrinsic value, MEV (range) | US$43 to US$61, point US$52 |
| PE / PEG | 14.6x trailing, 9.1x core forward / about 1.0 to 1.3 |
| Price vs intrinsic value | Undervalued by about 12% versus the point estimates |
| Margin of safety | About 13% |
| Free cash flow strong? | Yes: £4.0bn company-defined FCF in 2025, £2.8bn in H1 2026 |
| Balance sheet strong? | Adequate: net debt £15.1bn, about 1.4x EBITDA |
| Biggest single risk | Pipeline fails to replace dolutegravir sales after 2028 |
| Buy price, 9%/yr over 16 years | About US$41 (estimate, range US$35 to US$47) |
| Still buy if market closed 5 years? | Yes, at or below US$41 |
| Snapshot verdict | Hold (watchlist; near a buy) |
Exact inputs used for intrinsic value:
- Starting owner earnings: US$3.40 per ADS (about £5.0bn, between GSK’s own 2025 free cash flow of £4.0bn, which deducts licensing and contingent payments, and stockanalysis.com’s TTM operating cash flow less capex of £6.9bn; the midpoint judgment is mine)
- DCF: discount rate 9%; owner earnings growth 5% in years 1 and 2, 0% in years 3 to 5 (patent cliff), 4% in years 6 to 10, terminal growth 2%; owner earnings are after interest, so no net debt deduction
- MEV: normalised EPS of US$4.34 per ADS (160p per ordinary share, between 2025 core EPS of 172.0p and total EPS of 141.1p) times a fair PE of 12x (range 10x to 14x)
- Buy-price model: same normalised EPS, growth of 5% in 2027, 0% for 2028 to 2030, 5% for 2031 to 2035, 3% thereafter; exit PE 12x; dividends of 70p per share in 2026 (US$1.90 per ADS) growing with earnings
Deep Dive
Business Understanding
GSK discovers, licenses, makes and sells prescription medicines and vaccines. Revenue comes from governments, insurers and pharmacy benefit managers paying for patented products. Demand is stable and largely insensitive to the economy: people take HIV drugs and asthma inhalers in recessions. The business model is durable, but each product decays. A blockbuster earns high margins for ten years or so, then loses most of its sales within two years of generic entry.
That makes GSK a treadmill: it must spend about £6bn a year on research (unverified) and buy in assets to replace what expires. What would kill it? A run of pipeline failures coinciding with the dolutegravir patent expiry, plus US drug-pricing reform. The Zantac litigation, settled in 2024 for about £1.8bn (unverified), showed that legal tail risks also exist.
Competitive Advantage and Positioning
The moat is a combination of patents, regulatory approval and manufacturing expertise. Vaccines carry the deepest moat: making them at scale is very hard, and Shingrix has dominated shingles prevention for years. ViiV Healthcare is one of two leaders in HIV, alongside Gilead. Gilead’s newer drugs, including twice-yearly lenacapavir, are a serious challenge, and GSK is betting on long-acting injectables (Cabenuva, Apretude) to defend its share.
Pricing power is moderate and declining across the industry as US payers and policy push back. Main competitors include Gilead in HIV, Pfizer and Moderna in RSV vaccines, and AstraZeneca and Sanofi in respiratory medicine. The moat per product is strong but time-limited. Whether it is widening depends on the pipeline: Blenrep in myeloma (Q2 2026 sales £36m, more than doubling), depemokimab, a twice-yearly asthma biologic, and a new HIV portfolio. These are promising but not yet proven.
Financial Strength, Profitability
| Fiscal year | Revenue (£bn) | Operating income (£bn) | Total EPS (pence) | Core EPS (pence) | Dividend (pence) |
|---|---|---|---|---|---|
| 2021 | 24.70 | 5.63 | 108 | n/a (pre-Haleon split) | 100 |
| 2022 | 29.32 | 7.32 | 366 (includes Haleon gain) | 139.7 (unverified) | 61.3 |
| 2023 | 30.33 | 8.40 | 120 | about 156 (derived) | 58.0 |
| 2024 | 31.38 | 6.19 | 62 | 159.3 | 61.0 |
| 2025 | 32.67 | 9.45 | 141 | 172.0 | 66.0 |
| TTM to Jun 2026 | 33.20 | about 9.7 | 118 | about 182 (unverified) | 70 expected for 2026 |
Sales have grown about 7% a year since 2021, flattered by Arexvy’s launch, and core EPS has grown about 5% a year since 2022. Gross margin of 73% and operating margin of 29% are typical of large pharma. Reported earnings are far noisier than core earnings because of charges for the Zantac settlement in 2024, restructuring and changes in the value of contingent payments to ViiV’s partners. Q2 2026 total EPS was only 10.8p against core EPS of 50.5p; the cause was not verified. ROIC is 26% and ROE 33% on stockanalysis.com’s measures, but a multi-year ROIC series was not retrieved, so the trend is unverified.
Financial Strength, Balance Sheet
At 30 June 2026, net debt was £15.1bn, against EBITDA of roughly £11bn, or about 1.4x (stockanalysis.com). Debt has fallen from £24.2bn in 2021 to £18.3bn, helped by the Haleon separation. Total assets have shrunk from £79.1bn to £61.7bn over the same period.
Two flags deserve attention. Goodwill and intangibles total £24.2bn, more than shareholders’ equity of £17.2bn, which is normal for an acquisitive drug company. The current ratio is 0.82x and working capital is negative £4.0bn, manageable given predictable cash inflows. Contingent consideration owed to ViiV’s partners, Pfizer and Shionogi, acts like quasi-debt. A recession would not stress this balance sheet; a large litigation loss or acquisition could.
Financial Strength, Cash Flow
| Period | Operating cash flow (£bn) | Capex (£bn) | Company-defined FCF (£bn) |
|---|---|---|---|
| FY 2025 | about 7.7 (unverified) | about 1.4 | 4.03 |
| H1 2026 | n/a | n/a | 2.81 |
| TTM to Jun 2026 | 8.33 | 1.43 | n/a |
Free cash flow is positive and fairly stable, but definitions matter. GSK’s own measure deducts licensing purchases and contingent payments to ViiV partners. Those are real costs of staying on the treadmill, so I set owner earnings below the simple figure. In 2025 GSK paid £2.6bn in dividends and £1.4bn in buybacks, and it has now completed its £2bn programme. Shares outstanding are about 4.0bn ordinary shares (stockanalysis.com), down modestly. Capex is steady at about 4% of sales.
Margin of Safety
At US$46, GSK trades about 12% below both point estimates, a margin of safety of roughly 13%: enough for modest error only. If my valuation were 20% too high, fair value would be about US$42, and the stock would be slightly overvalued. If it were 30% too high, fair value would be about US$37, and buying at US$46 would mean a 20% overpayment. The dividend yield of about 4.1% provides additional cushion while the thesis plays out.
Mispricing Thesis
GSK is cheap because the market expects the dolutegravir patent cliff to stall earnings for three years, and because GSK has underperformed peers for a decade. Arexvy’s disappointing uptake, the Zantac overhang and US pricing politics reinforce the scepticism.
What may be missing: management says operating margin will remain “stable to improving” through the 2028 to 2030 cliff, and it is targeting more than £40bn of sales by 2031. If GSK meets even most of that, earnings would grow through the cliff, and a 9x core PE would look too low. The gap closes if Phase III readouts deliver in 2027 and 2028, especially in HIV and respiratory medicine. This mispricing is partly temporary (sentiment) and partly structural (patent expiry is real).
Management and Capital Allocation
Luke Miels, formerly chief commercial officer, became chief executive in January 2026, succeeding Emma Walmsley. His early moves look sensible: doubling Phase III trial starts to more than 20 in 2026, and a £1.9bn annual cost-savings programme by 2029, mostly reinvested in R&D. Capital allocation since the Haleon split has been disciplined: a rebased but progressive dividend, a £2bn buyback at modest valuations, and bolt-on acquisitions (such as Aiolos Bio and IDRx) rather than transformative mergers.
Executive pay is tied to core operating profit, sales, cash flow and pipeline milestones (unverified detail). Reliance on core measures is a mild concern because core excludes recurring charges. Insider ownership is negligible at 0.06%, and the new chief executive’s record is unproven.
Long-Term Outlook
Ageing populations support demand, and GSK’s franchises sit in large, durable markets. In five to ten years, GSK should be the same size or larger if the pipeline delivers. Disruption risk comes mainly from US policy: drug-price negotiation, tariff threats and changes to vaccine recommendations. In a recession, sales would barely move, and the dividend would be safe at a 40% to 45% payout of core earnings.
Risk Assessment
Permanent loss would most likely come from pipeline failure combined with a steep HIV decline. HIV was £7.7bn of 2025 sales, about 24% of the total, much of it dolutegravir-based. If replacements fail and sales fall 15% to 20% over 2028 to 2030, the shares could re-rate to US$35 to US$40 and stay there. Other risks: US pricing regulation, litigation, sterling weakness and overpaying for acquisitions.
Red Flag Scan
- Declining free cash flow: No; stable to rising.
- Rising debt without rising earnings: No; debt has fallen since 2021.
- Misaligned management pay: Mild; heavy reliance on core measures.
- Serial acquisitions: Moderate; frequent bolt-ons, which is how pharma replenishes pipelines, but deal size is disciplined so far.
- Accounting complexity: Yes; large, persistent gaps between core and total earnings, and contingent consideration remeasurements.
- Moat erosion: Partial; time-based erosion of the HIV franchise.
- Overreliance on one product: Moderate; HIV is about a quarter of sales.
- Other: Negative working capital; leadership change in 2026; US vaccine-policy uncertainty affecting Arexvy and Shingrix.
Disconfirming Evidence
The bear case: GSK has been “cheap” for a decade and has mostly stayed cheap, because its earnings never compound. Core EPS excludes charges that recur every year, so the real earnings base is closer to total EPS of 120p to 140p per share, putting the stock on 13x to 15x real earnings, not 9x. The HIV cliff will remove billions of high-margin sales from 2028, and Gilead’s long-acting drugs threaten the franchise even before then. Vaccines face a hostile US policy environment, and Arexvy has disappointed. A new chief executive is doubling R&D spending, which raises costs before revenues follow. The £40bn 2031 target relies on unapproved drugs, and big-pharma targets are often missed.
Why I still hold my view: The bear case is serious and is why my base case assumes flat earnings for three years and a modest 12x exit PE. Even so, the valuation works out to about US$52 to US$53, and the dividend pays investors to wait. I do not concede, but I accept that the margin of safety is thin and the stock is not a buy for the 9% hurdle at US$46.
Scenario Valuations
| Scenario | Owner earnings growth | Operating margin | Discount rate | Intrinsic value per ADS | Entry condition | Exit condition |
|---|---|---|---|---|---|---|
| Bear | 2% for two years, minus 4% to 6% a year for three years, then 2%; 1% terminal | Falls to about 25% | 10% | US$34 | Below US$30, after a failed key readout or HIV decline | Above US$42 |
| Base | 5%, 5%, then flat for three years, then 4%; 2% terminal | Stable at about 29% to 31% (core) | 9% | US$53 | Below US$41 | Above US$64, or thesis break |
| Bull | 8%, 7%, 3% through the cliff, then 5% to 6%; 2.5% terminal | Rising to about 33% | 8.5% | US$71 | Below US$53 | Above US$80 |
Buy Price and Margin of Safety
Method: the maximum buy price equals the present value, at the target return, of the dividends received plus the exit value at the end of the horizon. Dividends are included because GSK’s 4% yield is a large share of the total return. Exit value uses a 12x PE on projected normalised EPS. Projected 2042 normalised EPS is US$7.15 per ADS, giving an exit value of about US$86. Each result sits within a range of about plus or minus 15%.
Buy Price for Various Returns Over 16 Years
| Target annual return | Projected exit value (2042) | Maximum buy price |
|---|---|---|
| 5% | US$86 | US$65 |
| 6% | US$86 | US$58 |
| 7% | US$86 | US$51 |
| 8% | US$86 | US$46 |
| 9% | US$86 | US$41 |
| 10% | US$86 | US$37 |
Buy Price for 9% Annual Return Over Various Horizons
| Horizon | Projected EPS at exit (per ADS) | Exit value at 12x | Maximum buy price |
|---|---|---|---|
| 5 years | US$4.78 | US$57 | US$45 |
| 7 years | US$5.28 | US$63 | US$45 |
| 10 years | US$5.99 | US$72 | US$44 |
| 12 years | US$6.36 | US$76 | US$43 |
| 14 years | US$6.74 | US$81 | US$42 |
| 16 years | US$7.15 | US$86 | US$41 |
At US$46, the base case implies about 8.0% a year over 16 years, including dividends, just short of the 9% hurdle.
Sell Discipline
Thesis triggers for trimming or exiting:
- Two or more major Phase III failures among the seven assets management has prioritised
- Core operating margin falling below 27% during the dolutegravir cliff, contradicting management’s “stable to improving” guidance
- The 2031 sales outlook cut materially below £40bn
- A large, debt-funded acquisition pushing net debt above 2.5x EBITDA
- A dividend cut, which would signal management doubts cash flow durability
Valuation trigger: as a guide, a price above US$64 to US$70, the top of the base-case range and approaching the bull case, would warrant trimming, because further gains would require the bull case to play out.
Risk and Opportunity Profile
Risk sub-factors (10 = lowest risk):
| Sub-factor | Weight | Score | Weighted |
|---|---|---|---|
| Financial Stability | 0.30 | 7 | 2.10 |
| Earnings Volatility | 0.20 | 6 | 1.20 |
| Business Model Risk | 0.20 | 5 | 1.00 |
| Macro Sensitivity | 0.15 | 9 | 1.35 |
| Market Risk | 0.15 | 8 | 1.20 |
| Risk Score | 1.00 | 6.85 |
A score of 6.85 indicates below-average risk. Low macro sensitivity and a low beta of 0.29 help, while business model risk (patent expiry and pipeline dependence) is the main drag.
Opportunity sub-factors (10 = most favourable):
| Sub-factor | Weight | Score | Weighted |
|---|---|---|---|
| Growth Potential | 0.30 | 4 | 1.20 |
| Unit Economics | 0.20 | 8 | 1.60 |
| Competitive Advantage | 0.20 | 6 | 1.20 |
| Valuation Asymmetry | 0.20 | 6 | 1.20 |
| Catalysts | 0.10 | 6 | 0.60 |
| Opportunity Score | 1.00 | 5.80 |
A score of 5.80 indicates moderate opportunity. Strong unit economics and a reasonable valuation offset weak growth through 2030.
Classification
GSK is stable, with a growth spurt now and a plateau ahead. Peter Lynch would call it a stalwart with turnaround features: a large, steady company that can deliver 30% to 50% gains when bought cheaply, but not a fast grower. The post-Haleon reset and new leadership add a mild turnaround angle. Charlie Munger would likely see a fair business at a fair-to-cheap price. Pharma has excellent margins but must keep reinventing its product line, and that dependence on scientific outcomes he would consider hard to predict. He might note that GSK is cheaper than most peers for a reason.
De ROIC trend, 2025 operating cash flow, the Zantac settlement amount and the cause of weak Q2 2026 total EPS. These affect value by perhaps plus or minus 10% and support a medium, not high, confidence rating.
Summary and Verdict
GSK is a solid, cash-generative pharmaceutical business priced as though its best years are behind it. At US$46, it trades at about 9x core earnings and a 4.1% forward dividend yield, roughly 12% below my intrinsic value range of US$41 to US$64 (point US$53). The patent cliff for dolutegravir between 2028 and 2030 is the central risk; the pipeline and £40bn sales target are the central opportunity.
The stock does not quite meet the 9% over 16 years goal at US$46. The base case implies about 8% a year including dividends. It would meet the goal at about US$41 (range US$35 to US$47).
Verdict: Hold (watchlist). Buy range: US$35 to US$41. Fair value range: US$41 to US$64, with a bull case of about US$71.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a financial advisor before making investment decisions.
